China's BravoVax In-Licenses Rotavirus Vaccine for Infants

BravoVax of China in-licensed a rotavirus vaccine (RRV-TV) that can be administered to newborns, unlike competing vaccines, which are approved only for infants over the age of two months. The vaccine was developed by the International Medica Foundation of the US. BravoVax, a joint venture between Shanghai BravoBio and Humanwell Group of China, owns global rights to the vaccine except for the US, Europe and Japan. Financial details of the transaction were not disclosed. More details.... Stock Symbol: (SHA: 600079) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.